Literature DB >> 25035099

Cognition in patients with newly diagnosed brain metastasis: profiles and implications.

Adam Gerstenecker1, Louis B Nabors, Karen Meneses, John B Fiveash, Daniel C Marson, Gary Cutter, Roy C Martin, Christina A Meyers, Kristen L Triebel.   

Abstract

Cognitive impairment is a common symptom in patients with brain metastasis, and significant cognitive dysfunction is prevalent in a majority of patients who are still able to engage in basic self-care activities. In the current study, the neurocognitive performance of 32 patients with brain metastasis and 32 demographically-matched controls was examined using a battery of standardized neuropsychological tests, with the goal of comprehensively examining the cognitive functioning of newly diagnosed brain metastasis patients. The cognition of all patients was assessed within 1 week of beginning treatment for brain metastasis. Results indicated impairments in verbal memory, attention, executive functioning, and language in relation to healthy controls. Performance in relation to appropriate normative groups was also examined. Overall, cognitive deficits were prevalent and memory was the most common impairment. Given that cognitive dysfunction was present in this cohort of patients with largely minimal functional impairment, these results have implications for patients, caregivers and health care providers treating patients with brain metastasis.

Entities:  

Mesh:

Year:  2014        PMID: 25035099      PMCID: PMC4295820          DOI: 10.1007/s11060-014-1543-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

Review 1.  Frontal lobes and human memory: insights from functional neuroimaging.

Authors:  P C Fletcher; R N Henson
Journal:  Brain       Date:  2001-05       Impact factor: 13.501

2.  Neurocognitive dysfunction in cancer patients.

Authors:  C A Meyers
Journal:  Oncology (Williston Park)       Date:  2000-01       Impact factor: 2.990

3.  Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.

Authors:  E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-05-01       Impact factor: 7.038

Review 4.  Cognition and depression: current status and future directions.

Authors:  Ian H Gotlib; Jutta Joormann
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

5.  Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis.

Authors:  Jing Li; Soren M Bentzen; Jialiang Li; Markus Renschler; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

Review 6.  Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature.

Authors:  Christopher S Platta; Deepak Khuntia; Minesh P Mehta; John H Suh
Journal:  Am J Clin Oncol       Date:  2010-08       Impact factor: 2.339

7.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors:  Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

8.  Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Authors:  Minesh P Mehta; Patrick Rodrigus; C H J Terhaard; Aroor Rao; John Suh; Wilson Roa; Luis Souhami; Andrea Bezjak; Mark Leibenhaut; Ritsuko Komaki; Christopher Schultz; Robert Timmerman; Walter Curran; Jennifer Smith; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

9.  Distribution of brain metastases.

Authors:  J Y Delattre; G Krol; H T Thaler; J B Posner
Journal:  Arch Neurol       Date:  1988-07

10.  Neurocognitive and functional assessment of patients with brain metastases: a pilot study.

Authors:  Mary A Herman; Ivo Tremont-Lukats; Christina A Meyers; Dianna D Trask; Carrie Froseth; Markus F Renschler; Minesh P Mehta
Journal:  Am J Clin Oncol       Date:  2003-06       Impact factor: 2.339

View more
  19 in total

1.  Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer.

Authors:  Kenneth D Westover; J Travis Mendel; Tu Dan; Kiran Kumar; Ang Gao; Suprabha Pulipparacharuv; Puneeth Iyengar; Lucien Nedzi; Raquibul Hannan; John Anderson; Kevin S Choe; Wen Jiang; Ramzi Abdulrahman; Asal Rahimi; Michael Folkert; Aaron Laine; Chase Presley; C Munro Cullum; Hak Choy; Chul Ahn; Robert Timmerman
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

2.  Capacity of patients with brain metastases to make treatment decisions.

Authors:  Kristen L Triebel; Adam Gerstenecker; Karen Meneses; John B Fiveash; Christina A Meyers; Gary Cutter; Daniel C Marson; Roy C Martin; Amanda Eakin; Olivia Watts; Louis B Nabors
Journal:  Psychooncology       Date:  2015-01-23       Impact factor: 3.894

3.  Patients with brain metastasis and the risk of falls: a plausibly preventable entity.

Authors:  Alejandro Torres-Trejo; David M Peereboom
Journal:  Neurooncol Pract       Date:  2022-03-30

4.  Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.

Authors:  Esther J J Habets; Linda Dirven; Ruud G Wiggenraad; Antoinette Verbeek-de Kanter; Geert J Lycklama À Nijeholt; Hanneke Zwinkels; Martin Klein; Martin J B Taphoorn
Journal:  Neuro Oncol       Date:  2015-09-18       Impact factor: 12.300

5.  Enhancing Medical Decision-Making Evaluations: Introduction of Normative Data for the Capacity to Consent to Treatment Instrument.

Authors:  Adam Gerstenecker; Lindsay Niccolai; Daniel Marson; Kristen L Triebel
Journal:  Assessment       Date:  2015-08-17

6.  Neuropsychological profiles of breast cancer and brain tumor cohorts in Northeast Ontario, Canada.

Authors:  Matias Mariani; Mark William Glister Collins
Journal:  Support Care Cancer       Date:  2018-05-17       Impact factor: 3.603

7.  Impact of cognitive function on communication in patients with primary or secondary brain tumours.

Authors:  Diana N Naehrig; Eng-Siew Koh; Monica Vogiatzis; Waka Yanagisawa; Carol Kwong; Heather L Shepherd; Chris Milross; Haryana M Dhillon
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

Review 8.  Brain metastases: An update on the multi-disciplinary approach of clinical management.

Authors:  D K Mitchell; H J Kwon; P A Kubica; W X Huff; R O'Regan; M Dey
Journal:  Neurochirurgie       Date:  2021-04-14       Impact factor: 1.553

9.  Clinical evaluation of fitness to drive in patients with brain metastases.

Authors:  Cristina Valencia-Sanchez; Vanessa C Gorelkin; Maciej M Mrugala; Akanksha Sharma; Sujay A Vora; Jonathan B Ashman; Thomas B Daniels; Michele Y Halyard; William G Rule; Nan Zhang; Richard J Butterfield; Steven E Schild; Alyx B Porter
Journal:  Neurooncol Pract       Date:  2019-07-03

10.  Capacity to consent to research participation in adults with metastatic cancer: comparisons of brain metastasis, non-CNS metastasis, and healthy controls.

Authors:  Kyler Mulhauser; Dario A Marotta; Adam Gerstenecker; Gabrielle Wilhelm; Terina Myers; Meredith Gammon; David E Vance; Burt Nabors; John Fiveash; Kristen Triebel
Journal:  Neurooncol Pract       Date:  2020-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.